Dan said something to the effect of...they can reach proof of concept with 3 wholly-owned compounds before they even need to think about the need for additional financing. That sounded positive regarding the potential for near term dilution, but he has said similar things before. He said 901 enrollment was progressing well, but data in 2014, so the slow play on this continues and maybe that's the reason for additional selling. 289 sounds very exciting, if they can get in gear. Overall, Junius sounds tired from long days at ASCO. IMGN broke recent support, looks to be heading lower, but I think (hope) the people looking to buy at $15 will not get filled. IMGN always goes higher and mostly lower than I expect, so maybe it will happen. Looks like a buyable dip here and now, good luck traders!